Prognostic Value of Pre-operative Renal Insufficiency in Urothelial Carcinoma: A Systematic Review and Meta-Analysis

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Cao, Jian ^a,b   Zhao, Xiaokun ^a   Zhong, Zhaohui ^a   Zhang, Lei ^a   Zhu, Xuan ^a   Xu, Ran ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOMA; HUMAN; KIDNEY FAILURE; META ANALYSIS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; TUMOR RECURRENCE; URINARY TRACT TUMOR; UROTHELIUM;

CARCINOMA; HUMANS; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RENAL INSUFFICIENCY; UROLOGIC NEOPLASMS; UROTHELIUM;

EID: 84991508565     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep35214     Document Type: Article

References (47)

1. Roupret, M. et al. European association of urology guidelines on upper urinary tract urothelial cell carcinoma: 2015 update. European Urology 68, 868-879 (2015).
2. Torre, L. A. et al. Global Cancer Statistics, 2012. CA a cancer J. Clin. 65, 87-108 (2015).
3. Rabbani, F., Perrotti, M., Russo, P., Herr, H. W. Upper-tract tumors after an initial diagnosis of bladder cancer: argument for longterm surveillance. J. Clin. Oncol. 19, 94-100 (2001).
4. Matas, A. J., Simmons, R. L., Kjellstrand, C. M., Buselmeier, T. J., Najarian, J. S. Increased incidence of malignancy during chronic renal failure. Lancet 1, 883-886 (1975).
5. Cengiz, K. Increased incidence of neoplasia in chronic renal failure (20-year experience). Int. Urol. Nephrol. 33, 121-126 (2002).
6. Weinstein, S. J. et al. Serum Creatinine and Prostate Cancer Risk in a Prospective Study. Cancer Epidemiol. Biomarkers Prev. 18, 2643-2649 (2009).
7. Woldu, S. L. et al. Renal insufficiency is associated with an increased risk of papillary renal cell carcinoma histology. Int. Urol. Nephrol. 46, 2127-2132 (2014).
8. Merseburger, A. S., Connelly, R. R., Sun, L., Richter, E., Moul, J. W. Use of serum creatinine to predict pathologic stage and recurrence among radical prostatectomy patients. Urology 58, 729-734 (2001).
9. Rausch, S. et al. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression-Introducing a novel prognostic model for bladder cancer recurrence. Urol. Oncol. Semin. Orig. Investig. 32, 1178-1183 (2014).
10. Fang, D. et al. Risk factors and treatment outcomes of new contralateral upper urinary urothelial carcinoma after nephroureterectomy: the experiences of a large Chinese center. J. Cancer Res. Clin. Oncol. 140, 477-485 (2014).
11. Hinata, N. et al. Performance status as a significant prognostic predictor in patients with urothelial carcinoma of the bladder who underwent radical cystectomy. Int. J. Urol. 22, 742-746 (2015).
12. Fossa, S. D. et al. Survival after curative treatment of muscle-invasive bladder cancer. Acta Oncol. 35 Suppl 8, 59-65 (1996).
13. Fokdal, L., Høyer, M., von der Maase, H. Treatment outcome and prognostic variables for local control and survival in patients receiving radical radiotherapy for urinary bladder cancer. Acta Oncol. (Madr). 43, 749-757 (2004).
14. Hannisdal, E., Fosså, S. D., Høst, H. Blood tests and prognosis in bladder carcinomas treated with definitive radiotherapy. Radiother. Oncol. 27, 117-122 (1993).
15. Sengeløv, L., Kamby, C., Schou, G., von der Maase, H. Prognostic factors and significance of chemotherapy in patients with recurrent or metastatic transitional cell cancer of the urinary tract. Cancer 74, 123-133 (1994).
16. Chung, S.-D. et al. CKD as a Risk Factor for Bladder Recurrence After Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma. Am. J. Kidney Dis. 50, 743-753 (2007).
17. HUANG, P.-C. et al. High incidence of and risk factors for metachronous bilateral upper tract urothelial carcinoma in Taiwan. Int. J. Urol. 13, 864-869 (2006).
18. Ito, K. et al. Preoperative Risk Factors for Extraurothelial Recurrence in Patients with Ureteral Cancer Treated with Radical Nephroureterectomy. J. Urol. 191, 1685-1692 (2014).
19. Li, C.-C. et al. Significant predictive factors for prognosis of primary upper urinary tract cancer after radical nephroureterectomy in Taiwanese patients. Eur. Urol. 54, 1127-1134 (2008).
20. Thrasher, J. B., Frazier, H. A., Robertson, J. E., Dodge, R. K., Paulson, D. F. Clinical variables which serve as predictors of cancerspecific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer 73, 1708-1715 (1994).
21. Sakano, S. et al. Risk group stratification based on preoperative factors to predict survival after nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Ann. Surg. Oncol. 20, 4389-4396 (2013).
22. Morizane, S. et al. Preoperative prognostic factors after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Int. Urol. Nephrol. 45, 99-106 (2013).
23. Fosså, S. D. et al. Bladder cancer definitive radiation therapy of muscle-invasive bladder cancer. A retrospective analysis of 317 patients. Cancer 72, 3036-3043 (1993).
24. Yang, M. H. et al. Prognostic-factors-based risk-stratification model for invasive urothelial carcinoma of the urinary bladder in Taiwan. Urology 59, 232-238; discussion 238-9 (2002).
25. Pollack, A. et al. The relationship of local control to distant metastasis in muscle invasive bladder cancer. J. Urol. 154, 2059-2063; discussion 2063-4 (1995).
26. Spera, J. A., Whittington, R., Littman, P., Solin, L. J., Wein, A. J. A comparison of preoperative radiotherapy regimens for bladder carcinoma. The University of Pennsylvania experience. Cancer 61, 255-262 (1988).
27. Chen, C.-Y., Liao, Y.-M., Tsai, W.-M., Kuo, H.-C. Upper urinary tract urothelial carcinoma in eastern Taiwan: high proportion among all urothelial carcinomas and correlation with chronic kidney disease. J. Formos. Med. Assoc. 106, 992-998 (2007).
28. Fang, D. et al. Incidence, characteristics, treatment strategies, and oncologic outcomes of synchronous bilateral upper tract urothelial carcinoma in the Chinese population1These authors contribute equally. Urol. Oncol. Semin. Orig. Investig. 33, 661-6611 (2015).
29. Yafi, F. A. et al. Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: Assessment of adequate renal function and influence on outcome. Urol. Oncol. Semin. Orig. Investig. 32, 3117-3124 (2014).
30. Sengeløv, L., Kamby, C., Geertsen, P., Andersen, L. J., von der Maase, H. Predictive factors of response to cisplatin-based chemotherapy and the relation of response to survival in patients with metastatic urothelial cancer. Cancer Chemother. Pharmacol. 46, 357-364 (2000).
31. Ichioka, D. et al. Impact of renal function of patients with advanced urothelial cancer on eligibility for first-line chemotherapy and treatment outcomes. Jpn. J. Clin. Oncol. 45, 867-873 (2015).
32. Launay-Vacher, V. et al. Incidence of renal insufficiency in cancer patients and evaluation of information available on the use of anticancer drugs in renally impaired patients. Med. Sci. Monit. 10, CR209-CR212 (2004).
33. Launay-Vacher, V. et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: The renal insufficiency and anticancer medications (IRMA) study. Cancer 110, 1376-1384 (2007).
34. Karmarkar, S., MacNab, R. Fluid and electrolyte problems in renal dysfunction. Anaesth. Intensive Care Med. 13, 332-335 (2012).
35. Li, W.-M. et al. The prognostic predictors of primary ureteral transitional cell carcinoma after radical nephroureterectomy. J. Urol. 182, 451-458; discussion 458 (2009).
36. Barlow, L. J., Korets, R., Laudano, M., Benson, M., McKiernan, J. Predicting renal functional outcomes after surgery for renal cortical tumours: a multifactorial analysis. BJU Int. 106, 489-492 (2010).
37. Aapro, M., Launay-Vacher, V. Importance of monitoring renal function in patients with cancer. Cancer Treat. Rev. 38, 235-240 (2012).
38. Gupta, N. P. et al. Oncological and Functional Outcome of Radical Cystectomy in Patients With Bladder Cancer and Obstructive Uropathy. J. Urol. 178, 1206-1211 (2007).
39. Kato, S. et al. Aspects of immune dysfunction in end-stage renal disease. Clin. J. Am. Soc. Nephrol. 3, 1526-1533 (2008).
40. Oberg, B. P. et al. Increased prevalence of oxidant stress and inflammation in patients with moderate to severe chronic kidney disease. Kidney Int. 65, 1009-1016 (2004).
41. Vamvakas, S., Bahner, U., Heidland, A. Cancer in end-stage renal disease: potential factors involved-editorial. Am. J. Nephrol. 18, 89-95 (1998).
42. Stopper, H., Meysen, T., Böckenförde, A. Increased genomic damage in lymphocytes of patients before and after long-term maintenance hemodialysis therapy. Am. J. Kidney Dis. 34, 433-437 (1999).
43. Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., Grp, P. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement (Reprinted from Annals of Internal Medicine). Phys. Ther. 89, 873-880 (2009).
44. Stroup, D. F. et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283, 2008-2012 (2000).
45. Rector, T. S., Taylor, B. C., Wilt, T. J. Chapter 12: Systematic review of prognostic tests. Journal of General Internal Medicine 27, (2012).
46. Sutton, A. J., Abrams, K. R., Jones, D. R., Sheldon, T. a & Song, F. Methods for Meta-analysis in Medical Research. 309 (2000).
47. Tierney, J. F., Stewart, L. A., Ghersi, D., Burdett, S., Sydes, M. R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 8, 16 (2007).